ArticleMedicine2026
Combination of PD-1 inhibitor and chemotherapy for subcutaneous soft-tissue metastasis in postoperative non-small cell lung cancer: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
rationaleDespite available therapies, patients with advanced non-small cell lung cancer have a poor prognosis, highlighting the need for novel treatment strategies. The combination of immune checkpoint inhibitors and chemotherapy represents a promising approach. This case report describes the efficacy and safety of this combination in a patient with aggressive metastatic disease. PATIENT CONCERNS: A 60-year-old male patient, who had undergone surgical resection for primary lung adenocarcinoma, presented with newly developed subcutaneous nodules and symptoms suggestive of adrenal involvement during routine follow-up. DIAGNOSES: Histopathological and imaging examinations confirmed recurrent lung adenocarcinoma with metastases to the subcutaneous soft tissues and the adrenal gland.
interventionsThe patient received platinum-based doublet chemotherapy combined with pembrolizumab (an anti-programmed cell death protein 1inhibitor) as second-line systemic therapy. OUTCOMES: Following several treatment cycles, imaging revealed marked regression of metastatic lesions, with only minimal treatment-related adverse events reported. The patient achieved a durable clinical response. LESSONS: This case suggests that combining chemotherapy with programmed cell death protein 1 inhibition may provide rapid and effective tumor control in advanced non-small cell lung cancer patients with bulky, symptomatic metastases, while maintaining a manageable safety profile. Further clinical trials are warranted to validate this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.